Author: admin

Microbiome Diagnostics Market Size, Growth, Opportunities, Share, Key Segments, Regional Analysis, Top Companies and Forecast to 2028

“The Genetic Analysis (Norway) entered into an agreement with Eagle Biosciences Inc. (US) through its distributors with an undisclosed partner. A high-volume lab company providing laboratory diagnostics to clinics, public health departments and research universities in the US.”
The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

 Microbiome Diagnostics Market in terms of revenue was estimated to be worth $146 million in 2023 and is poised to reach $300 million by 2028, growing at a CAGR of 15.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The microbiome diagnostics market is driven by the growing demand of personalized medicine, the collaborative efforts between the microbiome industry and academia for microbiome research and increasing incidences of diseases in the microbiome-based diagnostics market. Growth in emerging countries and increased collaboration of industry players to work on new microbiome technology are anticipated to offer lucrative growth opportunities for the microbiome diagnostics market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132581140

The kits & reagents accounted for the largest share of the microbiome diagnostics market, by product segment, in 2022.

The global microbiome diagnostics market is segmented into instruments and reagents & kits based on product. High consumption of consumables such as kits and reagents and their repeated purchases along with the increasing number of microbiome diagnostic tests performed across the globe, are the factors supporting the growth of the reagents & kits product segment.

The hospitals segment accounted for the largest share of the microbiome diagnostics market, by end user, in 2022.

By end user, microbiome diagnostics market segmented into hospitals, research & academic institutes and, pharmaceutical & biotechnology companies. Hospitals are accounted for largest in the microbiome diagnostics market. The increasing prevalences of diseases such as gastrointestinal disorder, metabolic disorder etc. will boost the market growth.

North America is the largest regional market for microbiome diagnostics market.

The global microbiome diagnostics market has been segmented into four major regions—North America, Europe, the Asia Pacific, and Rest of the World. In 2022, North America dominated the global microbiome diagnostics market in 2022. The large share of the North American market is primarily driven by the prevalence of chronic diseases, and the easy accessibility of technologically advanced instruments.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132581140

Microbiome Diagnostics Market Dynamics:

Drivers:

  1. Growing prevalence of chronic diseases
  2. Collaborative efforts between microbiome industry and academia for microbiome research
  3. Growing demand for personalized medicine
  4. Rising awareness about importance of human microbiomes
  5. Rising funding and investments in microbiome research

Restraints:

  1. End-user budget constraints in developing countries

Opportunities:

  1. Increased collaboration between key players and small innovative companies to work on new microbiome technologies

Challenge:

  1. Adverse impact of complex regulatory policies on commercialization of microbiome

Key Market Players of Microbiome Diagnostics Industry:

The major players operating in this market are DNA Genotek (Canada), Microba Life Sciences (US), and Genetic Analysis AS (Norway)

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=132581140

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/microbiome-diagnostics-market-132581140.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Microbiome Diagnostics Market Size, Growth, Opportunities, Share, Key Segments, Regional Analysis, Top Companies and Forecast to 2028

Organ-on-Chip Market Worth $631,073 thousand | MarketsandMarkets™

“This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.”
Organ-on-Chip Market in terms of revenue was estimated to be worth $123,285 thousand in 2024 and is poised to reach $631,073 thousand by 2029, growing at a CAGR of 38.6% from 2024 to 2029 according to a new report by MarketsandMarkets™

Organ-on-Chip Market in terms of revenue was estimated to be worth $123,285 thousand in 2024 and is poised to reach $631,073 thousand by 2029, growing at a CAGR of 38.6% from 2024 to 2029 according to a new report by MarketsandMarkets™. Growth in the organ-on-chip market is mainly driven by factors such as growing emphasis on animal free drug testing, and an increase in the adoption of organ-on-chip technology by pharma and biotech companies for drug discovery and development. However, due to the limited scalability and low throughput of the current organ-on-chip technology, the use of this technology is restricted only to the pre-clinical drug development phase.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144117291

 

Disease-based model subsegment is the fastest-growing of the organ-on-chip market by model type

Among the model type subsegments, the market is segmented organ-based model and disease-based models. In 2023, the disease-based model segment accounted for the highest growth rate in the organ-on-chip market by model type. The high growth of this segment can be attributed to the growing adoption of disease-based models for progressing studies associated with several conditions along with an application of these models in personalized medicine development.

Liver-on-chip is the fastest-growing segment of the organ-on-chip market by organ type

Among the organ type subsegment, the organ-on-chip market is segmented into liver, kidney, lung, heart, intestine and other organs. In 2023, liver-on-chip segment accounted for the fastest-growing market of the organ type segment of organ-on-chip market. The high growth of this market segment can be attributed to the growing focus on animal-free drug discovery and development methods and increasing preclinical research to evaluate drug hepatotoxicity

Europe: The second-largest region in the organ-on-chip market.

The European market is the second-largest organ-on-chip market globally, mainly due to factors such as advancements in biofabrication technology and use of artificial intelligence in drug discovery and testing. The increased collaboration and partnership between private companies and government institutes along with increased awareness of the organ-on-chip technology are other important factors responsible for the size of the market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=144117291

Organ-on-Chip Market Dynamics:

Drivers:

  1. Increasing demand for animal-free testing
  2. Ethical concerns regarding use of animal models in drug development
  3. Growing drug discovery & development initiatives
  4. Development of personalized medicines
  5. Advancements in microfluidics and bioengineering
  6. Increased government and private funding
  7. Greater adoption of OOC technology by pharma & biotech companies

Restraints:

  1. Limitation of use restricted to preclinical trials
  2. Limited scalability and throughput

Opportunities:

  1. Development of human-on-a-chip models
  2. Increasing applications in diverse industries
  3. Developing hybrid business model providing both products and services

Challenge:

  1. Lack of standardization
  2. Mimicking complex tissues and organs

Key Market Players of Organ-on-Chip Industry:

Prominent players in the organ-on-chip market of Europe are MIMETAS B.V. (Netherlands), TissUse GmBH (Germany), Netri (France), Emulate, Inc. (US), CN Bio Innovations Ltd (UK), Insphero AG (Switzerland), SynVivo, Inc. (US), Nortis, Inc. (US), AxoSim, Inc. (US), Dynamic42 GmBH (Germany), React4Life (Italy), Obatala Sciences (US),  AlveoliX AG (Switzerland), BeOnChip S.L. (Spain), Initio Cell (Netherlands), Netri SAS (France), Hesperos, Inc. (US), Lena Biosciences (US), RevivoCell (UK), Altis Biosystems (US), Bi/ond (Netherlands), Biomimx S.R.L (Italy), Cherry Biotech (France), Fluigent (France), Elvesys (France)

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers – 45%, Directors- 30%, and Executives – 25%
  • By Country: North America- 40%, Europe- 30%, Asia Pacific- 20%, Latin America- 5%, and Middle East and Africa- 5%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=144117291

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/organs-on-chips-market-144117291.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Organ-on-Chip Market Worth $631,073 thousand | MarketsandMarkets™

Discover the Riveting Tale of Resilience and Mystery in “The Price” by Divya Reddy Meda

“”The Price,” published on June 21, 2024, by Austin Macauley Publishers, captures the essence of adolescence disrupted by unexplained relocations, compelling readers to ask: Who is Julia? Why does she have to move so often? And, most importantly, can she confront the horrifying fate that looms over her?”
Unravel the Secrets of Julia’s Turbulent High School Journey and Her Battle Against a Foreboding Fate

South Bend, IN – June 25, 2024 – High school is tough, but for Julia, it’s a battlefield of frequent moves and constant upheaval. In Divya Reddy Meda’s gripping new novel, “The Price,” readers are invited to delve into the mysterious life of a girl who faces relentless changes and an ominous destiny. “The Price,” published on June 21, 2024, by Austin Macauley Publishers,  captures the essence of adolescence disrupted by unexplained relocations, compelling readers to ask: Who is Julia? Why does she have to move so often? And, most importantly, can she confront the horrifying fate that looms over her? Divya Reddy Meda, an emerging author known for her dedication to community service, brings her unique perspective and heartfelt storytelling to this emotional thriller. Meda’s passion extends beyond the written word; she actively volunteers in orphanages and homes for the elderly and founded the NGO ‘Macle,’ which focuses on educating underprivileged children. Her multifaceted efforts reflect her commitment to making a positive impact through her literary works and social initiatives.

Praise for “The Price”

  • “The suspense had me on the edge of my seat from start to finish. I couldn’t put it down!”
  • “The plot twists kept me guessing until the very end. Just when I thought I had it figured out, the author threw another curveball.”
  • “The pacing was perfect – a great balance of fast-paced action sequences and slower moments to build the tension.”
  • “The author did an excellent job creating an ominous, foreboding atmosphere that really heightened the sense of danger.”

Don’t miss out on this compelling and emotionally charged story. “The Price” is available now. For more information about Divya Reddy Meda and her work, visit http://www.macle.org.

Discover Julia’s heart-pounding journey and uncover the mysteries within “The Price” today!

Media Contact

Website: www.macle.org

Email: dividanm@gmail.com

Phone: +1(574) 520-9921

https://www.linkedin.com/in/divyameda/

https://www.instagram.com/macle.tds?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

https://www.instagram.com/valorous_scripts?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Media Contact
Company Name: The Price
Contact Person: Divya Reddy Meda
Email: Send Email
Country: United States
Website: www.macle.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Discover the Riveting Tale of Resilience and Mystery in \”The Price\” by Divya Reddy Meda

Duchenne Muscular Dystrophy Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Duchenne Muscular Dystrophy Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Duchenne Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Duchenne Muscular Dystrophy Research. Learn more about our innovative pipeline today! @ Duchenne Muscular Dystrophy Pipeline Outlook

Key Takeaways from the Duchenne Muscular Dystrophy Pipeline Report

  • June 2024:- Edgewise Therapeutics Inc.- A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy.
  • June 2024:- Italfarmaco- Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy. This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant male paediatric (aged 9 to
  • June 2024:- Hoffmann-La Roche- A Phase II Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Pediatric Patients With Duchenne Muscular Dystrophy (SHIELD DMD). The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy (DMD) age ≥ 8 to < 16 years old receiving corticosteroid therapy.
  • June 2024:- Pfizer- The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year.
  • June 2024:- BioMarin Pharmaceutical- A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants With Duchenne Muscular Dystrophy. The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping.
  • June 2024:- Dyne Therapeutics- A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping. The primary purpose of this study is to evaluate the safety, tolerability, and dystrophin protein levels in muscle tissue following multiple intravenous (IV) doses of DYNE-251 in participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
  • DelveInsight’s Duchenne Muscular Dystrophy pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Duchenne Muscular Dystrophy treatment.
  • The leading Duchenne Muscular Dystrophy Companies such as Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others.
  • Promising Duchenne Muscular Dystrophy Therapies such as Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02, and others.

Stay informed about the cutting-edge advancements in Duchenne Muscular Dystrophy Treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Duchenne Muscular Dystrophy Clinical Trials Assessment

Duchenne Muscular Dystrophy Emerging Drugs

  • Vamorolone: Santhera

Vamorolone is a first-in-class drug candidate that binds to the same receptors as corticosteroids but modifies the downstream activity of the receptors1,2. This has the potential to ‘dissociate’ efficacy from typical steroid safety concerns and therefore could emerge as a valuable alternative to corticosteroids, the current standard of care in children and adolescent patients with DMD. There is a clear unmet medical need in this patient group as high dose corticosteroids have significant systemic side effects that detract from patient quality of life. On September 2, 2020, Santhera exercised its option and obtained worldwide rights to vamorolone in Duchenne muscular dystrophy and all other indications. Santhera and ReveraGen expect to complete the rolling NDA submission to the U.S. FDA in June 2022.

  • Givinostat: Italfarmaco

Givinostat, is an HDAC inhibitor (HDACi, a principle candidate, currently being developed for the treatment of DMD and BMD. Since Givinostat acts on the pathogenetic events downstream of the genetic defects, it is potentially a treatment for the whole DMD and BMD population and to counter the disease pathogenetic events in all muscular districts.

  • Pamrevlumab: Fibrogen

Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer and has been granted Orphan Drug Designation (ODD) in each of these indications, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD).

Learn more about Duchenne Muscular Dystrophy Drugs opportunities in our groundbreaking Duchenne Muscular Dystrophy Research and development projects @ Duchenne Muscular Dystrophy Unmet Needs

Duchenne Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

Duchenne Muscular Dystrophy Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Duchenne Muscular Dystrophy Treatment by visiting our website. Stay informed about how we’re transforming the future of musculoskeletal @ Duchenne Muscular Dystrophy Market Drivers and Barriers, and Future Perspectives

Scope of the Duchenne Muscular Dystrophy Pipeline Report

  • Coverage- Global
  • Duchenne Muscular Dystrophy Companies- Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others.
  • Duchenne Muscular Dystrophy Therapies- Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02, and others.
  • Duchenne Muscular Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Duchenne Muscular Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Duchenne Muscular Dystrophy Pipeline on our website @ Duchenne Muscular Dystrophy Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Duchenne Muscular Dystrophy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Duchenne Muscular Dystrophy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Delandistrogene moxeparvovec: Roche
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SRP 5051: Sarepta Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. WVE N531: Wave Life Sciences
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. EDG 5506: Edgewise Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Duchenne Muscular Dystrophy Key Companies
  21. Duchenne Muscular Dystrophy Key Products
  22. Duchenne Muscular Dystrophy- Unmet Needs
  23. Duchenne Muscular Dystrophy- Market Drivers and Barriers
  24. Duchenne Muscular Dystrophy- Future Perspectives and Conclusion
  25. Duchenne Muscular Dystrophy Analyst Views
  26. Duchenne Muscular Dystrophy Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Duchenne Muscular Dystrophy Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Metastatic Pancreatic Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Metastatic Pancreatic Cancer Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Metastatic Pancreatic Cancer pipeline landscape. It covers the Metastatic Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Pancreatic Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Metastatic Pancreatic Cancer Research. Learn more about our innovative pipeline today! @ Metastatic Pancreatic Cancer Pipeline Outlook

Key Takeaways from the Metastatic Pancreatic Cancer Pipeline Report

  • June 2024:- TME Pharma AG-An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients.
  • June 2024:- Cantex Pharmaceuticals- A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer. This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
  • June 2024:- iOnctura- A Phase 1b, Open Label, Dose Escalation Study of IOA-289, an Orally Bioavailable, Selective Autotaxin (ENPP2) Inhibitor Alone and in Combination With Gemcitabine/Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer. The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard chemotherapy consisting of gemcitabine and nab-paclitaxel.
  • June 2024:- Mirati Therapeutics Inc.- A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2. This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
  • DelveInsight’s Metastatic Pancreatic Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Metastatic Pancreatic Cancer treatment.
  • The leading Metastatic Pancreatic Cancer Companies such as Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
  • Promising Metastatic Pancreatic Cancer Therapies such as Antroquinonol, MRTX849, Pembrolizumab, Cetuximab, MRTX849, TNO155, Gemcitabine, and others.

Stay informed about the cutting-edge advancements in Metastatic Pancreatic Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Metastatic Pancreatic Cancer Clinical Trials Assessment

Metastatic Pancreatic Cancer Emerging Drugs

  • Motixafortide: BioLineRx

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.

  • Fuzuloparib: Jiangsu Hengrui Pharmaceuticals

Fuzuloparib is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs.

  • HP518: Hinova Pharmaceuticals

HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

Learn more about Metastatic Pancreatic Cancer Drugs opportunities in our groundbreaking Metastatic Pancreatic Cancer Research and development projects @ Metastatic Pancreatic Cancer Unmet Needs

Metastatic Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

Metastatic Pancreatic Cancer Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Metastatic Pancreatic Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Metastatic Pancreatic Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Pancreatic Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Metastatic Pancreatic Cancer Companies- Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
  • Metastatic Pancreatic Cancer Therapies- Antroquinonol, MRTX849, Pembrolizumab, Cetuximab, MRTX849, TNO155, Gemcitabine, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Pancreatic Cancer Pipeline on our website @ Metastatic Pancreatic Cancer Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Pancreatic Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Pancreatic Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Rucaparib: Eleison Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MDB 401 B: Panbela Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SBP 101: Takeda Oncology
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Pancreatic Cancer Key Companies
  21. Metastatic Pancreatic Cancer Key Products
  22. Metastatic Pancreatic Cancer- Unmet Needs
  23. Metastatic Pancreatic Cancer- Market Drivers and Barriers
  24. Metastatic Pancreatic Cancer- Future Perspectives and Conclusion
  25. Metastatic Pancreatic Cancer Analyst Views
  26. Metastatic Pancreatic Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Pancreatic Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2024” report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Colorectal Cancer Research. Learn more about our innovative pipeline today! @ Colorectal Cancer Pipeline Outlook

Key Takeaways from the Colorectal Cancer Pipeline Report

  • June 2024:- Seagen Inc.- An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
  • June 2024:- Merck Sharp & Dohme LLC- A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)
  • June 2024:- Mirati Therapeutics Inc.- This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.
  • June 2024:- Leap Therapeutics, Inc.– Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe). This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced CRC patients.
  • June 2024:- AbbVie- A Phase 1b Study to Evaluate Safety and Pharmacokinetics (PK) of ABBV-400 in Chinese Subjects With Unresectable Locally Advanced/Metastatic Colorectal Cancer. Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and how ABBV-400 moves through the body of adult participants with unresectable locally advanced/metastatic CRC.
  • DelveInsight’s Colorectal Cancer pipeline report depicts a robust space with 195+ active players working to develop 200+ pipeline therapies for Colorectal Cancer treatment.
  • The leading Colorectal Cancer Companies such as Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc, Neogap Therapeutics AB, Criterium, Inc, Daiichi Sankyo, Inc, Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
  • Promising Colorectal Cancer Therapies such as Niraparib, Dostarlimab, QL1706, Bevacizumab, Oxaliplatin injection, Botensilimab, Balstilimab, Trametinib, Ipilimumab, and others.

Stay informed about the cutting-edge advancements in Colorectal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Colorectal Cancer Clinical Trials Assessment

Colorectal Cancer Emerging Drugs Profile

  • XL092 : Exelixis

XL092 is an investigational small molecule, oral tyrosine kinase inhibitors (TKI) that inhibits the activity of receptor tyrosine kinases involved in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes like oncogenesis, metastasis, and tumor angiogenesis. Currently it is in Phase III stage of clinical trial evaluation to treat Colorectal Cancer.

  • Adagrasb : Mirati Therapeutics

Adagrasib is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers. The drug candidate is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated colorectal cancer. Currently being evaluated in the Phase III studies.

  • Olaparib : Merck Sharp & Dohme LLC/Astrazeneca

Olaparib is an investigational is a first-in-class Poly (ADP-ribose) polymerase PARP inhibitors and the first targeted treatment that potentially exploit DNA damage response (DDR) pathway deficiencies, like BRCA mutations, to preferentially kill cancer cells. Olaparib is being jointly developed and commercialized by AstraZeneca and Merck. Currently the drug is being evaluated in Phase III for the treatment of Colorectal Cancer.

  • DS-8201: Daiichi Sankyo

DS-8201 a proprietary antibody-drug conjugate (ADC) is a smart chemotherapy comprised of a humanized HER2 antibody attached to a novel topoisomerase I inhibitor payload by a tetra peptide-based linker. It is designed to target and deliver chemotherapy inside cancer cells and reduce systemic exposure to the cytotoxic payload (or chemotherapy) compared to the way chemotherapy is commonly delivered. The drug is been developed in collaboration with AstraZeneca. The drug is in Phase II stage of clinical trials.

  • Ompenaclid: Inspirna

Ompenaclid is a first in class oral small molecule inhibitor of the creatine transport channel SLC6A8 a novel target that is enriched under hypoxic conditions and provides tumor cells with an additional energy source. Ompenaclid triggers tumor regressions in CRC patients by inducing apoptosis of tumor cells. It is based on Rgenix technology. The drug is in Phase II stage of clinical trials.

  • LYL845: Lyell Immunopharma

LYL845, an autologous tumor-infiltrating lymphocytes (TIL). It is administered through the intravenous route. It is being developed based on an ex vivo epigenetic reprogramming (Epi-R) technology platform is currently being investigated in a Phase 1 clinical trial in patients suffering with relapsed or refractory metastatic colorectal cancer.

  • RG6286: Genentech

RG6286 (BLYG-8824A) is under development for the treatment of relapsed or refractory, advanced, or metastatic colorectal cancer. It is new chemical entity, administered through an intravenous route currently being investigated in a Phase 1 clinical trial.

Learn more about Colorectal Cancer Drugs opportunities in our groundbreaking Colorectal Cancer Research and development projects @ Colorectal Cancer Unmet Needs

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Colorectal Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Colorectal Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Colorectal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Colorectal Cancer Companies- Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc, Neogap Therapeutics AB, Criterium, Inc, Daiichi Sankyo, Inc, Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
  • Colorectal Cancer Therapies- Niraparib, Dostarlimab, QL1706, Bevacizumab, Oxaliplatin injection, Botensilimab, Balstilimab, Trametinib, Ipilimumab, and others.
  • Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Colorectal Cancer Pipeline on our website @ Colorectal Cancer Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Colorectal Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Comparative Analysis
  8. XL092: Exelixis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Early Stage Products (Phase I)
  12. LYL845: Lyell Immunopharma
  13. Inactive Products
  14. Colorectal Cancer Key Companies
  15. Colorectal Cancer Key Products
  16. Colorectal Cancer – Unmet Needs
  17. Colorectal Cancer – Market Drivers and Barriers
  18. Colorectal Cancer – Future Perspectives and Conclusion
  19. Colorectal Cancer Analyst Views
  20. Colorectal Cancer Key Companies
  21. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape. It covers the Chronic Inflammatory Demyelinating Polyneuropathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Inflammatory Demyelinating Polyneuropathy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Chronic Inflammatory Demyelinating Polyneuropathy Research. Learn more about our innovative pipeline today! @ Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Outlook

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report

  • June 2024:- Immunovant Sciences GmbH– A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
  • June 2024:- Janssen Research & Development LLC- Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
  • DelveInsight’s Chronic Inflammatory Demyelinating Polyneuropathy pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Chronic Inflammatory Demyelinating Polyneuropathy treatment.
  • The leading Chronic Inflammatory Demyelinating Polyneuropathy Companies such as Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies Inc., and others.
  • Promising Chronic Inflammatory Demyelinating Polyneuropathy Therapies such as Riliprubart, Batoclimab 680 mg, SAR445088, Panzyga, Efgartigimod PH20 SC, Nipocalimab, IgPro10, Immunoadsorption, TAK-771, and others.

Stay informed about the cutting-edge advancements in Chronic Inflammatory Demyelinating Polyneuropathy Treatments. Download for updates and be a part of the revolution in inflammatory disease care @ Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials Assessment

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs Profile

  • HYQVIA: Takeda

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins. It contains immunoglobulins collected from human plasma. The drug is infused under the skin into the fatty subcutaneous tissue. The hyaluronidase part of HYQVIA helps more of the Ig get absorbed into the body. The drug is approved for adults with primary immunodeficiency, and in adults, children and adolescents with PI and with secondary immunodeficiency. While it is in Phase III trial for CIDP.

  • Rozanolixizumab: UCB S.A.

Rozanolixizumab is a subcutaneously administered, humanized monoclonal antibody that specifically binds, with high affinity, to the human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and Immunoglobulin G (IgG), accelerating the catabolism of antibodies and reducing the concentration of pathogenic IgG autoantibodies. The drug is under clinical development with the aim of improving the lives of people with pathogenic IgG-autoantibody-driven autoimmune diseases, including ITP, myasthenia gravis (MG), and CIDP, by driving the removal of pathogenic IgG autoantibodies.

  • Temelimab: GeNeuro SA

Temelimab is a monoclonal antibody designed to neutralize a pathogenic viral envelope protein, encoded by a member of the Human Endogenous Retrovirus-W family, pHERV-W. This protein is thought to be a causal factor in several diseases, including multiple sclerosis, Type 1 diabetes and CIDP. It neutralizes the pHERV-W Env protein without targeting the patient’s immune system, and could be a treatment that is both safe and effective in slowing or stopping the disease’s progress in all its forms. By neutralizing pHERV-W env, GNbAC1 could at the same time block these pathological inflammatory processes and restore remyelination in patients. The drug is currently in Phase I trial for the treatment of CIDP patients.

Learn more about Chronic Inflammatory Demyelinating Polyneuropathy Drugs opportunities in our groundbreaking Chronic Inflammatory Demyelinating Polyneuropathy Research and development projects @ Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs

Chronic Inflammatory Demyelinating Polyneuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Chronic Inflammatory Demyelinating Polyneuropathy Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Discover the latest advancements in Chronic Inflammatory Demyelinating Polyneuropathy Treatment by visiting our website. Stay informed about how we’re transforming the future of Neurology @ Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report

  • Coverage- Global
  • Chronic Inflammatory Demyelinating Polyneuropathy Companies- Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies Inc., and others.
  • Chronic Inflammatory Demyelinating Polyneuropathy Therapies- Riliprubart, Batoclimab 680 mg, SAR445088, Panzyga, Efgartigimod PH20 SC, Nipocalimab, IgPro10, Immunoadsorption, TAK-771, and others.
  • Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Chronic Inflammatory Demyelinating Polyneuropathy Pipeline on our website @ Chronic Inflammatory Demyelinating Polyneuropathy Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Inflammatory Demyelinating Polyneuropathy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Inflammatory Demyelinating Polyneuropathy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. HYQVIA: Takeda
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Rozanolixizumab: UCB S.A.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Temelimab: GeNeuro SA
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic Inflammatory Demyelinating Polyneuropathy Key Companies
  21. Chronic Inflammatory Demyelinating Polyneuropathy Key Products
  22. Chronic Inflammatory Demyelinating Polyneuropathy- Unmet Needs
  23. Chronic Inflammatory Demyelinating Polyneuropathy- Market Drivers and Barriers
  24. Chronic Inflammatory Demyelinating Polyneuropathy- Future Perspectives and Conclusion
  25. Chronic Inflammatory Demyelinating Polyneuropathy Analyst Views
  26. Chronic Inflammatory Demyelinating Polyneuropathy Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Inflammatory Demyelinating Polyneuropathy Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Drip Irrigation Market worth $8.6 billion by 2029 | Key Players are The Toro Company, Rain Bird Corporation, Elgo Irrigation Ltd., Antelco, and Grupo Chamartin S.A.

“MarketsandMarkets™”
Drip Irrigation Market Report by Component (Emitters/Drippers, Drip Tubes/Drip Mainlines, Filters & Fertilizer Injectors, Fittings & Accessories, Pressure Pumps & Valves), Crop Type, Application, Emitter/Dripper Type, & Region – Global Forecast to 2029

The global drip irrigation market is estimated at USD 5.6 billion in 2024 and is projected to reach USD 8.6 billion by 2029, at a CAGR of 9.0% during the forecast period. The need for drip irrigation is driven by increasing global demand for food security, water scarcity concerns, and the imperative to enhance agricultural productivity sustainably. Drip irrigation addresses these needs by efficiently delivering water and nutrients directly to plant roots, minimizing wastage, and optimizing crop yields. Factors driving the drip irrigation market include advancements in technology such as AI and IoT integration, government incentives promoting water-efficient practices, expansion of commercial farming, and the rising adoption of precision agriculture techniques. These factors collectively propel the growth of drip irrigation systems, meeting the challenges of modern agriculture while ensuring environmental sustainability.

Drip Irrigation Market

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=217216582

By component, filters & fertilizer injectors consititute to grow at consistent rate in the drip irrigation market.

Filters are essential components that prevent clogging of emitters and drip lines by filtering out particles and debris from the irrigation water. They help maintain consistent water flow and distribution, thereby optimizing irrigation performance and reducing maintenance downtime. Fertilizer injectors, on the other hand, enable precise and controlled application of fertilizers and nutrients directly into the irrigation system. This capability ensures that crops receive the right amount of nutrients at the right time, promoting healthier plant growth and maximizing yield potential. The increasing adoption of drip irrigation systems worldwide, coupled with advancements in filter technology and fertilization practices, underscores the rising demand for filters and fertilizer injectors as integral components of efficient and sustainable agricultural practices.

In the crop type segment, vegetable crops constitutes significant share in the drip irrigation market.

Drip irrigation systems are becoming increasingly popular in vegetable cultivation across various crops such as tomatoes, peppers, and cucumbers. These systems offer precise water and nutrient delivery directly to the root zones of plants, which is crucial for optimizing growth and yield. For tomatoes, consistent moisture levels provided by drip irrigation promote even fruit development and reduce blossom-end rot, a common issue with fluctuating soil moisture. Peppers benefit from controlled irrigation that enhances fruit quality and uniformity, while cucumbers thrive with the targeted application of water, reducing soil moisture fluctuations that can lead to fruit deformities. The efficiency and effectiveness of drip irrigation in these vegetables not only improve crop health and yield but also contribute to sustainable farming practices by conserving water and minimizing environmental impact.

Make an inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=217216582

The Europe region is projected to grow at consistent rate during forecast period in drip irrigation market.

The drip irrigation market in Europe is driven by several factors contributing to its growth and adoption. Firstly, increasing awareness and regulations promoting sustainable water management practices propel the demand for efficient irrigation technologies like drip systems. These regulations aim to conserve water resources and minimize environmental impact, encouraging farmers to invest in water-saving irrigation solutions. Secondly, the expansion of commercial agriculture and horticultural sectors in Europe necessitates precision irrigation methods to optimize crop yields and quality. Drip irrigation systems offer precise water and nutrient delivery directly to plant roots, enhancing crop health and productivity.

Key players in this market include Rivulis (Isarel), The Toro Company (US), Jain Irrigation Systems Ltd. (India), HUNTERS INDUSTRIES INC. (US), NETAFIM (Isarel), Mahindra EPC Irrigation Limited  (India), Rain Bird Corporation (US), Chinadrip Irrigation Equipment (Xiamen) Co., Ltd.  (China), Elgo Irrigation Ltd. (Isarel), Shanghai Irrist Corp., Ltd. (China), Antelco (Australia), Microjet Irrigation Systems (South Africa), metzer (Isarel), Grupo Chamartin S.A. (Spain), and Azud (Spain).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=217216582

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/drip-irrigation-systems-market-217216582.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Drip Irrigation Market worth $8.6 billion by 2029 | Key Players are The Toro Company, Rain Bird Corporation, Elgo Irrigation Ltd., Antelco, and Grupo Chamartin S.A.

Fit Fashion Wigs Reveals New Collection of 100% Premium Human Hair Glueless Wigs

Fit Fashion Wigs Launches New Line of Beginner’s Favorite, Pre-Styled Human Hair Wigs, Blending Luxury with Ease for All Users.

Irvine, CA – Fit Fashion Wigs, a forerunner in premium human hair wigs, announces the launch of its new collection that merges style, comfort, and ease for enthusiasts and first-time users alike. This latest launch includes standout products like the 200% Density Water Wave Lace Front Wig, 200% Density Kinky Straight Lace Front Wig, 180% Density Body Wave Lace Front Wig, and the 180% Density Jerry Curly Lace Front Wig, all designed to enhance the beauty regimen of its users effortlessly.

The 200% Density Water Wave Lace Front Wig, made from 100% premium human hair, offers luxurious waves with a natural look. Its high density provides fullness and volume, making it perfect for those looking to make a statement. The pre-plucked hairline and added baby hair around the edges ensure a seamless blend with the wearer’s natural hairline.

The 200% Density Kinky Straight Lace Front Wig delivers a unique texture that mimics natural afro hair, providing a voluminous and full-bodied look. This wig is perfect for users who desire a natural yet bold style. The pre-bleached knots and glueless design make it easy to install and wear, ensuring comfort and style throughout the day.

The 180% Density Body Wave Lace Front Wig stands out with its elegant wave pattern that holds beautifully under any condition. Crafted from high-quality Burmese human hair, this piece transitions effortlessly from daytime wear to glamorous evening styles. Its lightweight yet dense construction ensures comfort without compromising on volume, making it ideal for extended wear.

The 180% Density Jerry Curly Lace Front Wig, made from 100% Burmese hair, features luxurious, voluminous curls and a seamless 13×4 HD lace front that aligns perfectly with the wearer’s hairline. Pre-bleached and pre-plucked, this wig is a beginner’s favorite, ensuring that anyone can achieve a professional salon look right at home. The innovative design includes added baby hair around the edges, amplifying the wig’s natural appearance and feel.

“Fit Fashion Wigs is dedicated to providing premium, fashion-forward products that cater to the diverse needs of our clientele,” stated the CEO of Fit Fashion Wigs. “Our wigs are designed not just for appearance but for the utmost in comfort and ease, making them perfect for anyone looking to enhance their style.”

Each wig in the collection is designed with a breathable cap for all-day comfort and minimal shedding to maintain the hair’s lush, bouncy look. The versatility of the styles offered allows wearers to experiment with different looks, whether they prefer their hair down or styled up.

Beyond aesthetics, Fit Fashion Wigs is committed to innovation in the application process. All featured products are glueless, minimizing the fuss and mess often associated with traditional wig applications. This approach not only saves time but also protects the user’s natural hair and scalp.

Customers interested in experiencing the blend of luxury, comfort, and style offered by Fit Fashion Wigs can explore the collection and make purchases directly through the company’s website at https://fitfashionwigs.com.

About Fit Fashion Wigs:

Fit Fashion Wigs is renowned for its high-quality, 100% premium human hair wigs that blend sophistication with practicality. Catering to a diverse client base, the company prioritizes customer satisfaction with designs that emphasize natural appearance and user-friendly features.

Media Contact
Company Name: Pulse Media PR
Contact Person: Rachel Harris
Email: Send Email
Country: United States
Website: https://fitfashionwigs.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fit Fashion Wigs Reveals New Collection of 100% Premium Human Hair Glueless Wigs

Food Fortifying Agents Market Trends, Growth Opportunities, Industry Overview, Top Companies, and Forecast – 2027

“MarketsandMarkets™”
Food Fortifying Agents Market by Type (Minerals, Vitamins, Carbohydrates, Prebiotics, Probiotics), Application (Cereal & Cereal-based Products, Bulk Food Items), Process (Drum Drying, Dusting) and Region – Global Forecast to 2027

The global food fortifying agents market is estimated to reach $128.0 billion by 2027, growing at a 10.1% compound annual growth rate (CAGR). The global market size was valued $79.3 billion in 2022. With such remarkable figures on the horizon, the global market is undoubtedly one to watch out for.The food fortifying agents industry is poised for significant expansion in response to the growing emphasis on health and wellness among consumers. With a surge in demand for products that offer added nutritional benefits, there is a unique opportunity for innovation and growth in the market. As the aging population grows and health concerns become more prevalent, the adoption of food fortifying agents for a variety of applications is expected to increase on a large scale. This trend is set to drive the market forward, creating new avenues for manufacturers and suppliers to cater to the evolving needs of health-conscious consumers.

Food Fortifying Agents Market

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72061350

The Evolution of the Food Fortifying Agents Market

Over the past few decades, the food fortifying agents market has experienced remarkable evolution. Initially, the process was straightforward, such as adding iodine to salt to prevent goiter. However, it has since developed into a sophisticated industry that produces a diverse array of additives to enhance foods with essential nutrients. This market growth is driven by several factors. A primary factor is the increasing awareness of the importance of a balanced diet and the critical role essential nutrients play in maintaining optimal health. Additionally, with the rising prevalence of chronic diseases like obesity and diabetes, consumers are increasingly seeking foods that are not only delicious but also beneficial for their health.

Increasing demand for fortifying agents in dietary supplements

The primary factor driving the demand for food fortifying agents is the increasing popularity of dietary supplements. As lifestyles evolve, consumer awareness about the benefits of dietary supplements has grown. There has been a significant rise in the consumption of vitamins, minerals, immunity-boosting foods, organic products, and various dietary aids. Higher disposable incomes and greater health consciousness among consumers have spurred the shift towards nutraceuticals, including dietary supplements. Consequently, more people are opting for multivitamins and minerals in capsule and tablet form due to lifestyle changes and a heightened focus on fitness and health.

The rising consumption of omega-3 fatty acids to reduce the risk if chronic heart diseases

Lipids are a diverse group of naturally occurring molecules that include waxes, fats, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), monoglycerides, triglycerides, diglycerides, and phospholipids. Among these, omega-3 and omega-6 fatty acids are essential lipids that are commonly used.

Omega-3 fatty acids, a type of polyunsaturated fatty acid (PUFA), are essential for health. They can be found in fish such as tuna, salmon, and halibut, as well as in algae, krill, certain plants, and nut oils. Consuming omega-3 fatty acids has been shown to reduce the risk of various health issues, including heart disease, prostate and breast cancers, high blood pressure, osteoporosis, bipolar disorder, depression, skin disorders, asthma, and arthritis. The American Heart Association recommends eating fish, especially fatty varieties like mackerel, lake trout, herring, sardines, albacore tuna, and salmon, at least twice a week to promote better health.

Make an Inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=72061350

Asia Pacific region is witnessing the highest growth rate in the market.

The food fortifying agents market in the Asia Pacific region is experiencing significant growth, driven by the busy lifestyles and increasing disposable incomes of consumers. The demand for these agents is expected to rise rapidly due to growing consumer interest. Among these agents, proteins and amino acids are expanding particularly quickly. Key markets in this region include China, India, Japan, and Australia & New Zealand, which boast extensive agricultural areas and produce high-fiber plants and oilseeds—primary raw materials for fiber and specialty carbohydrate ingredients.

The processed food industry in the Asia Pacific is also expanding, fueled by changing consumer lifestyles. The food and beverage sector is undergoing a substantial transformation, prompted by rapid urbanization, diet diversification, and the liberalization of foreign direct investment in the food industry. Increasing incomes and purchasing power, along with a rising demand for nutritional and healthy products, present promising opportunities for growth and diversification in the region’s food sector, further boosting the demand for food fortifying agents.

Top Companies in the Food Fortifying Agents Market

The key players in this market include Cargill (US), DSM (Netherlands), CHR. Hansen Holdings A/S (Denmark), DuPont (US), BASF SE (Germany), Arla Foods Amba (Denmark), Tate & Lyle (UK), Ingredion (US), Archer Daniels Midland Company (US), and Nestle SA (Switzerland).

Cargill is involved in the manufacturing and marketing of food ingredients, agricultural products, risk management, financial, and industrial products & services around the globe. Cargill operates in 70 countries through its subsidiaries and affiliates. The company manufactures and markets food fortifying agents such as oils & fats, grains & oil seeds. The company distributes its wide range of indigenous and imported vegetable oils, fats and flour products to household customers as well as food industries in over 125 countries at a global level. Its geographical network spans North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Its subsidiaries include The Mosaic Company (US), NatureWorks LLC (US), and The Wilbur Chocolate Company (US).

DSM is the one of the leading companies providing specialized solutions for health, nutrition & Bioscience. DSM offers a wide range of products for animal nutrition & health, human nutrition, care & health, food & beverage and materials. The company supplies food & beverage, dietary supplements, early-life nutrition and medical nutrition, whereas in animal nutrition & health is the leading supplier of feed additives such as vitamins, carotenoids, eubiotics, and feed enzymes. The company provides scientific & innovative solutions to 23,000 people throughout the world. The company has geographical presence across North America, Europe, Asia Pacific, Latin America, Netherlands, Switzerland and Rest of the World. Its subsidiaries include DSM Nutritional products AG, GLYCOM A/S, Fortitech, Inc., and Vitatene S.A.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=72061350

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/food-fortifying-agents-market-72061350.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Food Fortifying Agents Market Trends, Growth Opportunities, Industry Overview, Top Companies, and Forecast – 2027